



Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

4.26.21

TORONTO,
CANADA

-

April

26,

2021

-

[Cybin](#)

[Inc.](#)

[\(NEO:CYBN\)](#)

[\(OTCQB:CLXPF\)](#)

“Cybin”

or

the



[Our Work](#)

[Investors](#)

[About Us](#)

biotechnology
company
focused
on
progressing
psychedelic
therapeutics,
today
announced
that
it
has
selected
Alcohol
Use
Disorder
("AUD")
as
the
initial
target
indication
for
its
proprietary
deuterated
psychedelic



Our Work

Investors

About Us

AUD
is
a
chronic
relapsing
brain
disorder
characterized
by
an
impaired
ability
to
stop
or
control
alcohol
use
despite
adverse
social,
occupational,
or
health
consequences.¹
Approximately
5.8



Our Work

Investors

About Us

14.4 million adults in the United States ages 18 and older had AUD in 2018. This includes 9.2 million men and 5.3 million women.¹ To be diagnosed



[Our Work](#)

[Investors](#)

[About Us](#)

individuals
must
meet
certain
criteria
outlined
in
the
Diagnostic
and
Statistical
Manual
of
Mental
Disorders
("DSM").
Under
DSM-
5,
the
current
version
of
the
DSM,
anyone
meeting



Our Work

Investors

About Us

of
the
11
criteria
during
the
same
12-
month
period
receives
a
diagnosis
of
AUD.
The
severity
of
AUD
—
mild,
moderate,
or
severe
—
is
based



Our Work

Investors

About Us

number
of
criteria
met.¹

"The
evidence
of
increased
alcohol
use
during
this
ongoing
pandemic
is
startling.

For
so
many
individuals
and
families,
Alcohol
Use
Disorder
can
be



[Our Work](#)

[Investors](#)

[About Us](#)

devastating.

We

are

optimistic

that

CYB003

could

have

the

potential

to

improve

the

lives

of

AUD

sufferers

and

their

loved

ones

by

providing

a

durable

respite

from



[Our Work](#)

[Investors](#)

[About Us](#)

and the potential to overcome this often-crippling disease,” stated Doug Drysdale, Chief Executive Officer.

Cybin is confident that its proprietary deuterated CYB003 New Chemical Entity (“NCE”)



[Our Work](#)

[Investors](#)

[About Us](#)

an
ideal
investigational
new
drug
("IND")
candidate
for
a
future
AUD
clinical
trial
once
further
pre-
clinical
data
has
been
collected.
Cybin
is
targeting
an
IND
filing



[Our Work](#)

[Investors](#)

[About Us](#)

by
the
end
of
calendar
2021.

Cybin's
intellectual
property-
driven
strategy
focuses
on
the
discovery
of
NCEs
derived
from
parent
molecules
with
the
potential
to
be
faster



Our Work

Investors

About Us

more
commercially
viable
with
an
optimized
duration
of
action,
utilizing
proprietary
deuteration
processes.

As
the
psychedelic
industry
continues
to
evolve
with
positive
studies,
Cybin
believes
that
these



[Our Work](#)

[Investors](#)

[About Us](#)

have
the
potential
to
fill
current
unmet
treatment
needs
for
various
psychiatric
and
neurological
conditions.

**Alcohol-
Related
Emergencies
and
Deaths
in
the
United
States²**



Our Work

Investors

About Us

•



Our Work

Investors

About Us



Our Work

Investors

About Us

•



Our Work

Investors

About Us

•

•



Our Work

Investors

About Us

Global Burden²

-



Our Work

Investors

About Us

•



Our Work

Investors

About Us



Our Work

Investors

About Us

•



Our Work

Investors

About Us



Our Work

Investors

About Us

health/alcohol-
use-
disorder

²<https://www.niaaa.nih.gov/publications/brochu>
and-
fact-
sheets/alcohol-
facts-
and-
statistics

About

Cybin

Cybin

is

a

leading

biotechnology

company

focused

on

progressing

psychedelic

therapeutics

by

utilizing



Our Work

Investors

About Us

discovery
platforms,
innovative
drug
delivery
systems,
novel
formulation
approaches
and
treatment
regimens
for
psychiatric
disorders.

**Cautionary
Notes
and
Forward-
Looking
Statements**

Certain
statements
in
this



[Our Work](#)

[Investors](#)

[About Us](#)

related
to
the
Company
are
forward-
looking
statements
and
are
prospective
in
nature.
Forward-
looking
statements
are
not
based
on
historical
facts,
but
rather
on
current
expectations



Our Work

Investors

About Us

about
future
events
and
are
therefore
subject
to
risks
and
uncertainties
which
could
cause
actual
results
to
differ
materially
from
the
future
results
expressed
or
implied
by



[Our Work](#)

[Investors](#)

[About Us](#)

looking
statements.
These
statements
generally
can
be
identified
by
the
use
of
forward-
looking
words
such
as
“may”,
“should”,
“could”,
“intend”,
“estimate”,
“plan”,
“anticipate”,
“expect”,
“believe”
or



[Our Work](#)

[Investors](#)

[About Us](#)

the
negative
thereof
or
similar
variations.
Forward-
looking
statements
in
this
news
release
may
include
statements
regarding
enhanced
liquidity,
the
value
of
additional
capital
markets
exposure,
access



Our Work

Investors

About Us

and
retail
investors,
the
Company's
new
strategic
brand
messaging
campaign,
and
psychedelic
drug
development
programs
to
potentially
treat
mental
health
disorders.
There
are
numerous
risks
and
uncertainties



Our Work

Investors

About Us

cause
actual
results
and
Cybin's
plans
and
objectives
to
differ
materially
from
those
expressed
in
the
forward-
looking
information.

Actual
results
and
future
events
could
differ
materially



[Our Work](#)

[Investors](#)

[About Us](#)

anticipated
in
such
information.
These
and
all
subsequent
written
and
oral
forward-
looking
information
are
based
on
estimates
and
opinions
of
management
on
the
dates
they
are



[Our Work](#)

[Investors](#)

[About Us](#)

are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cybin makes



[Our Work](#)

[Investors](#)

[About Us](#)

treatment

or

health

benefit

claims

about

Cybin's

proposed

products.

The

U.S.

Food

and

Drug

Administration,

Health

Canada

or

other

similar

regulatory

authorities

have

not

evaluated

claims

regarding



[Our Work](#)

[Investors](#)

[About Us](#)

tryptamine,
tryptamine
derivatives
or
other
psychedelic
compounds
or
nutraceutical
products.

The
efficacy
of
such
products
has
not
been
confirmed
by
approved
research.

There
is
no
assurance
that



[Our Work](#)

[Investors](#)

[About Us](#)

of
psilocybin,
psychedelic
tryptamine,
tryptamine
derivatives
or
other
psychedelic
compounds
or
nutraceuticals
can
diagnose,
treat,
cure
or
prevent
any
disease
or
condition.
Vigorous
scientific
research
and
clinical



[Our Work](#)

[Investors](#)

[About Us](#)

needed.
Cybin
has
not
conducted
clinical
trials
for
the
use
of
its
proposed
products.
Any
references
to
quality,
consistency,
efficacy
and
safety
of
potential
products
do
not



Our Work

Investors

About Us

Cybin
verified
such
in
clinical
trials
or
that
Cybin
will
complete
such
trials.
If
Cybin
cannot
obtain
the
approvals
or
research
necessary
to
commercialize
its
business,
it



Our Work

Investors

About Us

a
material
adverse
effect
on
Cybin's
performance
and
operations.

*The
NEO
Exchange
has
neither
approved
nor
disapproved
the
contents
of
this
news
release
and
is*



Our Work

Investors

About Us

*for
the
adequacy
and
accuracy
of
the
contents
herein.*

Investor

Contacts:

Tim

Regan/Scott

Eckstein

KCSA

Strategic

Communications

Cybin@kcsa.com

Lisa

M.

Wilson

In-

Site



[Our Work](#)

[Investors](#)

[About Us](#)

lwilson@insitecony.com

Media

Contacts:

John

Kanakis

Cybin

Inc.

John@cybin.com

Annie

Graf

KCSA

Strategic

Communications

agraf@kcsa.com

Faith

Pomeroy-

Ward

In-

Site



[Our Work](#)

[Investors](#)

[About Us](#)

Faith@insitecony.com

[PREVIOUS POST](#)

[NEXT POST](#)



5600-100 King St W, Toronto ON
M5X 1C9
Investor Contact: ir@cybin.com
General Contact: info@cybin.com

Our Work

[Development Pipeline](#)

[The Science](#)

[Cybin x Kernel](#)

Investors

[Press Releases](#)

[Financials](#)

[Corporate Governance](#)

[Downloads](#)

About Us

[Mission](#)

[Team](#)

[News](#)

[Join Us](#)

[Contact](#)



Our Work

Investors

About Us